You are here
Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: CLL/SLL is generally very responsive to chemoimmunotherapy. However, relapses occur and resistance develops. In particular, del(17p) is associated with poor outcomes using all currently available treatments. Effective targeted therapies are needed. Ibrutinib, a first-in-class covalent inhibitor of Bruton tyrosine kinase, showed single-agent activity and mild toxicity in treatment-naïve (TN) (Lancet Oncology 2013) and relapsed/refractory (R/R) CLL (NEJM 2013) in the phase 1b/2 study (PCYC-1102). We present independent assessment of efficacy data 3 years following initiation of therapy to confirm and further characterize the durability of response. Methods: Analyses are based upon all patients (pts) treated from first dose on PCYC-1102 until data cut-off on the long-term follow-up study PCYC-1103. Patients received 420 or 840 mg ibrutinib daily. Best overall response rate (ORR) was assessed using iwCLL criteria. Results: Of 132 CLL/SLL (31 TN, 101 R/R) pts evaluated, the median age was 68 years (range, 37–84), with 61% aged ≥ 65 years; 36 (27.3%) pts (2 TN, 34 R/R) had del(17p) and 36 (27.3%) had del(11q). R/R pts including 34 with Del(17p) had a median of 4 (range, 1–12) prior therapies. The updated ORR (by independent review) was 78.0% for all-treated pts (83.9% TN-, 76.2% R/R and 55.9% for those R/R with del(17p)). Additionally, 5 R/R pts, 2 with del(17p), had a best response of PR with lymphocytosis. Median DOR was not reached for all-treated pts, and was 25.0 months (range, 4.8–34.3) in pts with del(17p). Median time on study was 29.4 months (range, 0.7–38.1) for all-treated pts, and 27.3 months (range, 0.9–37.5) for R/R pts with del(17p). More pts receiving prior therapy experienced serious or ≥ Grade 3 adverse events that decreased after 1 year on treatment. No new safety signals were observed in long-term follow-up; 64% of pts remain on treatment with ibrutinib. Conclusions: Single-agent ibrutinib showed durable responses in pts with TN or R/R CLL/SLL including those with del(17p), as independently confirmed with 3 years of follow-up.
Abstracts by Susan Mary O'Brien:
ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse.Meeting: 2014 ASCO Annual Meeting | Abstract No: 7074
- Meeting: 2014 ASCO Annual Meeting | Abstract No: 7080
Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.Meeting: 2014 ASCO Annual Meeting | Abstract No: 7118
Educational Book Articles by Susan Mary O'Brien:
- Source: 2010 Educational Book
Presentations by Susan Mary O'Brien:
Meeting: 2011 ASCO Annual Meeting
Session: Chronic Lymphocytic Leukemia Therapy: An Update on Frontline and Novel Therapies (Education Session)
Meeting: 2010 ASCO Annual Meeting
Session: Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia (Education Session)